Clinical trial • Neurology
A-dopamine for Parkinson's disease
Clinical trial of A-dopamine for Parkinson's disease. 2 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Parkinson's disease
Key dates
- Initial CTIS Submission Date
- 20-06-2025
- First CTIS Authorization Date
- 20-08-2025
Trial design
Clinical trial across 1 site in France.
- Target Sample Size
- 2
- Trial Duration For Participant
- 365
Recruitment
- Planned Sample Size
- 2
- Recruitment Window Months
- 12
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 2
France
- Earliest CTIS Part Ii Submission Date
- 06-08-2025
- Latest Decision Or Authorization Date
- 20-08-2025
- Processing Time Days
- 14
- Number Of Sites
- 1
- Number Of Participants
- 2
Sites
- Site Name
- Centre Hospitalier Universitaire De Lille
- Department Name
- Neurology
- Contact Person Name
- Caroline MOREAU
- Contact Person Email
- caroline.moreau@chu-lille.fr
- Number Of Participants
- 2
Sponsor
Primary sponsor
- Full Name
- Centre Hospitalier Universitaire De Lille
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- A-dopamine (anaerobic dopamine)
- Active Substance
- A-dopamine
- Routes Of Administration
- Intracerebroventricular
- Route
- Intracerebroventricular
Related trials
Other published trials that may interest you.